Lifecore Biomedical, Inc. Common Stock earnings per share and revenue
On Jan 02, 2026, LFCR reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.19 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 32.99 million, with a --% difference.
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.22 USD, with revenue projected to reach 32.20 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Lifecore Biomedical, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Lifecore Biomedical, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Lifecore Biomedical, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Lifecore Biomedical, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 01, 2026.
What are the forecasts for Lifecore Biomedical, Inc. Common Stock's next earnings report?
Based on 7
analysts, Lifecore Biomedical, Inc. Common Stock is expected to report EPS of -$0.22 and revenue of $32.20M for Q3 2026.